AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium Difficile Infection in Adults

Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium Difficile Infection in Adults

August 21, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2015-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics platform company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SER-109, an oral therapeutic currently in a Phase 2 clinical trial for the prevention of recurrent Clostridium Difficile infection (CDI) in adults. SER-109 is being investigated as a new therapeutic modality to treat recurrent CDI by correcting a dysbiosis of the human microbiome, which is an underlying cause of the condition.

Visterra Announces Publication of Data Demonstrating the Effectiveness of VIS410 Against Seasonal and Potential Pandemic Influenza Strains

Visterra Announces Publication of Data Demonstrating the Effectiveness of VIS410 Against Seasonal and Potential Pandemic Influenza Strains

August 18, 2015

– Preclinical Studies Published in the Proceedings of the National Academy of Sciences –

Seventh Sense Biosystems Receives Four Patent Allowances for TAP Blood Collection System in the US and Europe

Seventh Sense Biosystems Receives Four Patent Allowances for TAP Blood Collection System in the US and Europe

August 17, 2015

US Patent Allowed for Breakthrough Blood Sampling and Testing Technology

Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results

Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results

August 13, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the second quarter ended June 30, 2015, and recent business highlights.

Editas Medicine Raises $120 Million to Advance Genome Editing

Editas Medicine Raises $120 Million to Advance Genome Editing

August 10, 2015

-- Highly Oversubscribed Financing Brings Together World-Class Syndicate to Invest in CRISPR/Cas9 Medicines --

-- Proceeds to Expand Editas’ Genome Editing Platform and to Advance Multiple Therapeutic Programs -- 

BIND Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update

BIND Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update

August 6, 2015

- Preliminary interim data from iNSITE 1 clinical trial remains on track for fourth quarter of 2015 -

- Second Accurin candidate, AZD-2811, to enter clinic in fourth quarter of 2015 -

- Progress made developing next-generation Accurin product concepts for multiple therapeutic areas -

- Management to host conference call today at 8:30 a.m. EDT -

Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update

Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update

August 6, 2015

- Phase 2 study initiated for lead microbiome therapeutic SER-109 for prevention of recurrent Clostridium difficile infection (CDI) in adults

- FDA Breakthrough Therapy Designation received for SER-109

- Successfully completed initial public offering 

Acceleron Pharma Reports Second Quarter 2015 Financial and Operational Results

Acceleron Pharma Reports Second Quarter 2015 Financial and Operational Results

August 6, 2015

- Completed luspatercept myelodysplastic syndromes phase 2 clinical trial -

- FDA Fast Track Designations granted to luspatercept for the treatment of patients with beta-thalassemia -

- Phase 3 clinical trials with luspatercept in lower risk myelodysplastic syndromes and beta-thalassemia expected to begin by year-end 2015 -